Monitoring Parameters for Entresto (Sacubitril/Valsartan) in HFrEF
Patients taking Entresto require regular monitoring of blood pressure, renal function (serum creatinine/eGFR), and serum potassium, with particular vigilance during initiation and dose titration. 1, 2
Essential Monitoring Parameters
Blood Pressure Monitoring
- Monitor blood pressure closely during initiation and with each dose escalation 3, 4
- Symptomatic hypotension should be addressed through patient education and counseling, potentially reducing diuretic doses in non-congested patients rather than discontinuing Entresto 3
- Asymptomatic hypotension (even systolic BP <110 mmHg) should not prevent initiation or uptitration, as efficacy is maintained regardless of baseline blood pressure 3, 5
- If symptomatic hypotension occurs, temporarily reduce the dose rather than permanently discontinuing therapy—40% of patients requiring temporary dose reduction can subsequently be restored to target doses 3
Renal Function Monitoring
- Monitor serum creatinine and eGFR routinely, especially when used with aldosterone antagonists 1, 3
- Worsening renal function may require dose adjustment of Entresto and other medications 1
- Mild creatinine elevation (<0.5 mg/dL increase) is acceptable and does not require dose adjustment 3
- For severe renal impairment (eGFR <30 mL/min/1.73 m²), start at half the usual dose (24/26 mg twice daily) 4
Electrolyte Monitoring
- Serial measurement of serum potassium is critical because hyperkalemia may complicate therapy with angiotensin receptor blockers and aldosterone antagonists 1, 2
- Caution when serum potassium levels >5.0 mmol/L, particularly when Entresto is combined with mineralocorticoid receptor antagonists 2
- Regular checks of serum potassium should be performed according to clinical status 2
- Monitor for hyponatremia, which may be a sign of disease progression and is associated with impaired survival 1
Timing of Monitoring
During Initiation
- Check blood pressure, renal function, and potassium before starting therapy 3, 4
- Monitor closely during the first 2-4 weeks when titrating from starting dose (49/51 mg twice daily) to target dose (97/103 mg twice daily) 3, 5
During Maintenance Therapy
- Continue routine monitoring of serum electrolytes and renal function in all patients with heart failure 1
- Frequency should be adjusted based on clinical status, particularly in patients with impaired renal function or those taking aldosterone antagonists 2
Additional Monitoring Considerations
Natriuretic Peptide Monitoring
- While NT-proBNP levels decrease with Entresto therapy (40-65% reduction over time), using BNP measurements to guide dose titration has not been shown to improve outcomes more effectively than achieving target doses proven in clinical trials 1, 4
- BNP levels (a neprilysin substrate) paradoxically increase with Entresto, while NT-proBNP (not a neprilysin substrate) decreases 4
Angioedema Surveillance
- Monitor for signs and symptoms of angioedema, particularly in patients with prior history of angioedema with ACE inhibitors or ARBs 5, 4
- A 36-hour washout period is mandatory when switching from an ACE inhibitor to avoid angioedema risk 3, 4
Common Monitoring Pitfalls to Avoid
- Do not permanently reduce doses due to asymptomatic hypotension or mild laboratory changes—temporary dose reductions with subsequent re-titration are more appropriate 3
- Do not discontinue therapy for mild renal function changes—mild creatinine elevation is acceptable 3
- Do not fail to titrate to target doses (97/103 mg twice daily) as this provides maximum mortality benefit 3, 5
- Do not use medium-range doses as maintenance therapy—they do not provide most of the benefits of target doses 3